ArticleVaccine2026
V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
V-safe is an active surveillance system developed during the pandemic to monitor COVID-19 vaccine safety. After vaccination, US residents could enroll to receive text messages linked to health check-in surveys. Questions about symptoms and health impacts, including inability to complete daily activities, attend work or school, or receipt of medical care were asked at daily, weekly, and monthly intervals after vaccination. We describe demographics of participants compared to the vaccinated population, trends in enrollment, participation over time, and self-reported health impacts in the V-safe population during the COVID-19 pandemic. During December 14, 2020 - June 30, 2023, 9,609,282 persons completed at least one V-safe survey. Most were female (62.2%), aged 25-64 years (69.2%), and received an mRNA vaccine (95.0%). Compared to the US vaccinated population, a higher proportion of participants were non-Hispanic White or Asian and ≥ 75 years. Most registered for V-safe within the first few months after vaccination was recommended for their age group. Most completed an initial health survey within the first week after vaccination. Participation decreased for successive doses, especially among persons aged <18 years. Health impacts were reported more frequently during the first week post-vaccination, after dose 2 compared to dose 1, and among recipients of mRNA-1273 vaccine compared to recipients of BNT162b2 vaccine. Health impacts among children <12 years were reported slightly less frequently compared to adults. Seeking medical care was reported in the first week after vaccination by 0.8-1.2% of adults after doses 1-6 of an mRNA vaccine. Findings were similar to those in previous V-safe analyses and data from clinical trials. Rapidly decreasing participation during the course of the pandemic suggests that incentives encouraging survey completion in V-safe could be useful for improving safety monitoring for future emergency vaccines. V-safe continues to collect data about COVID-19 vaccines, with an emphasis on new products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.